Clinical trialNCT05787587Active, not recruitingPhase 1Interventional

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

SponsorIDEAYA BiosciencesEnrollment216Advanced or Metastatic Solid TumorsBreast CancerColorectal CancerEndometrial CancerExtensive Stage Small Cell Lung Cancer (ES-SCLC)Head and Neck Cancers+3 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Darrin Beaupre, MD,PhD
IDEAYA Biosciences
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Honorhealth Research Institute
Phoenix, Arizona, United States
the Angeles Clinic
Los Angeles, California, United States
Hoag Memorial Hospital
Newport Beach, California, United States
California Pacific Medical Center
San Francisco, California, United States
Sarah Cannon Research Institute
Denver, Colorado, United States
Yale University
New Haven, Connecticut, United States
Orlando Health
Orlando, Florida, United States
Emory University
Atlanta, Georgia, United States
Osf St Francis Medical Center
Peoria, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
Dana Faber Cancer Institute
Boston, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Columbia University Medical Center
New York, New York, United States
Weil Cornell University
New York, New York, United States
Sarah Cannon Research Institute - Oklahoma University
Oklahoma City, Oklahoma, United States
Sarah Cannon Research Institute - Thomas Jefferson University
Philadelphia, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Md Anderson
Houston, Texas, United States
Next Oncology
Irving, Texas, United States
Next Oncology
San Antonio, Texas, United States
Start Mountain Region
West Valley City, Utah, United States
Next Oncology
Fairfax, Virginia, United States
Swedish Cancer Institute
Seattle, Washington, United States
University of Wisconsin
Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IDE-161Pembrolizumab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Apr 2023
Primary completion: 31 Oct 2026
Completion: 31 May 2027
Last update posted: 13 Jul 2026
Registered enrollment: 216
Registry id: NCT05787587

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.